Catalent, Inc. (CTLT) Shares Sold by Engineers Gate Manager LP
Engineers Gate Manager LP decreased its stake in shares of Catalent, Inc. (NYSE:CTLT) by 32.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,392 shares of the company’s stock after selling 32,038 shares during the period. Engineers Gate Manager LP’s holdings in Catalent were worth $2,610,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Acrospire Investment Management LLC boosted its stake in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares during the period. Quantbot Technologies LP raised its holdings in shares of Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after purchasing an additional 1,804 shares during the period. Fortaleza Asset Management Inc. acquired a new stake in shares of Catalent during the third quarter worth $164,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Catalent by 12.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares during the period. Finally, Advisor Group Inc. increased its holdings in shares of Catalent by 1.3% in the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after acquiring an additional 65 shares during the period. 99.49% of the stock is owned by hedge funds and other institutional investors.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction dated Tuesday, November 21st. The stock was bought at an average price of $39.22 per share, for a total transaction of $294,150.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 1.70% of the company’s stock.
Catalent, Inc. (NYSE CTLT) opened at $39.23 on Thursday. The stock has a market cap of $5,055.30, a PE ratio of 26.61, a P/E/G ratio of 2.45 and a beta of 1.41. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. Catalent, Inc. has a 12-month low of $23.09 and a 12-month high of $43.39.
Catalent (NYSE:CTLT) last announced its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. Catalent had a net margin of 5.01% and a return on equity of 23.97%. Catalent’s revenue was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.16 EPS. equities analysts forecast that Catalent, Inc. will post 1.46 earnings per share for the current fiscal year.
A number of analysts recently weighed in on the stock. BidaskClub raised shares of Catalent from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Wells Fargo & Company increased their price objective on shares of Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a report on Wednesday, September 20th. Bank of America reaffirmed a “buy” rating and issued a $45.00 price objective (up previously from $40.00) on shares of Catalent in a report on Wednesday, September 20th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Catalent in a report on Tuesday, August 29th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $38.00 price objective (up previously from $35.00) on shares of Catalent in a report on Tuesday, August 29th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and an average target price of $44.25.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.